CytoDyn to Offer No-Cost Exploratory Laboratory Testing for Childhood Inflammatory Disease Associated with COVID-19 – The Bakersfield Californian
Posted: May 16, 2020 at 3:49 am
VANCOUVER, Washington, May 15, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (CytoDyn or the Company), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, today announced it is offering comprehensive cytokine profiling (including RANTES levels) through its diagnostic partner company, IncellDx, to help physicians understand the pathogenesis of Childhood Inflammatory Disease Related to COVID-19. These laboratory tests are exploratory in nature and not intended for clinical decision making.
Recent reports in parts of the U.S. and Europe suggest a rare and potentially fatal inflammatory disease linked to the novel coronavirus is afflicting a small number of children. The condition resembles a rare childhood illness called Kawasaki disease, which has similar signs and symptoms and can lead to enlargement of blood vessels that in severe forms may cause heart damage.
New York State Department of Health is investigating 110 reported cases and 3 deaths in children - predominantly school-aged - experiencing symptoms similar to Kawasaki disease and toxic shock-like syndrome, possibly due to COVID-19.
Bruce Patterson, M.D., Chief Executive Officer and founder of IncellDx, a diagnostic partner and an advisor to CytoDyn commented, Cytokines are proteins that modulate the inflammatory response. Kawasaki disease has been previously shown to be associated with elevated levels of RANTES, a protein we have shown to be significantly elevated in mild-moderate COVID-19 and over 100 times normal in critical COVID-19 patients.
Nader Pourhassan, Ph.D., President and Chief Executive Officer of CytoDyn added, We hope our comprehensive cytokine testing will help physicians gain a better understanding of the disease process and, in turn, explore the prospect for leronlimab to potentially provide a therapeutic benefit to children suffering from inflammatory illness related to COVID-19.
About Coronavirus Disease 2019CytoDyn is currently enrolling patients in two clinical trials for COVID-19, a Phase 2 randomized clinical trial for mild-to-moderate COVID-19 population in the U.S. and a Phase 2b/3 randomized clinical trial for severe and critically ill COVID-19 population in several hospitals throughout the country.
SARS-CoV-2 was identified as the cause of an outbreak of respiratory illness first detected in Wuhan, China. The origin of SARS-CoV-2 causing the COVID-19 disease is uncertain, and the virus is highly contagious. COVID-19 typically transmits person to person through respiratory droplets, commonly resulting from coughing, sneezing, and close personal contact. Coronaviruses are a large family of viruses, some causing illness in people and others that circulate among animals. For confirmed COVID-19 infections, symptoms have included fever, cough, and shortness of breath. The symptoms of COVID-19 may appear in as few as two days or as long as 14 days after exposure. Clinical manifestations in patients have ranged from non-existent to severe and fatal. At this time, there are minimal treatment options for COVID-19.
About Leronlimab (PRO 140) and BLA Submission for the HIV Combination Therapy The FDA has granted a Fast Track designation to CytoDyn for two potential indications of leronlimab for deadly diseases. The first as a combination therapy with HAART for HIV-infected patients and the second is for metastatic triple-negative breast cancer. Leronlimab is an investigational humanized IgG4 mAb that blocks CCR5, a cellular receptor that is important in HIV infection, tumor metastases, and other diseases, including NASH. Leronlimab has completed nine clinical trials in over 800 people, including meeting its primary endpoints in a pivotal Phase 3 trial (leronlimab in combination with standard antiretroviral therapies in HIV-infected treatment-experienced patients).
In the setting of HIV/AIDS, leronlimab is a viral-entry inhibitor; it masks CCR5, thus protecting healthy T cells from viral infection by blocking the predominant HIV (R5) subtype from entering those cells. Leronlimab has been the subject of nine clinical trials, each of which demonstrated that leronlimab could significantly reduce or control HIV viral load in humans. The leronlimab antibody appears to be a powerful antiviral agent leading to potentially fewer side effects and less frequent dosing requirements compared with daily drug therapies currently in use.
The Company filed its BLA for Leronlimab as a Combination Therapy for Highly Treatment Experienced HIV Patients with the FDA on April 27, 2020, and submitted additional FDA requested clinical datasets on May 11, 2020. After the BLA submission is deemed completed, the FDA sets a PDUFA goal date. CytoDyn has Fast Track designation for leronlimab and a rolling review for its BLA, as previously assigned by the FDA, and the Company plans to request a priority review for the BLA. A priority review designation means the FDAs goal is to take action on the marketing application within six months of receipt (compared with 10 months under standard review).
In the setting of cancer, research has shown that CCR5 may play a role in tumor invasion, metastases, and tumor microenvironment control. Increased CCR5 expression is an indicator of disease status in several cancers. Published studies have shown that blocking CCR5 can reduce tumor metastases in laboratory and animal models of aggressive breast and prostate cancer. Leronlimab reduced human breast cancer metastasis by more than 98% in a murine xenograft model. CytoDyn is, therefore, conducting a Phase 1b/2 human clinical trial in metastatic triple-negative breast cancer and was granted Fast Track designation in May 2019.
The CCR5 receptor appears to play a central role in modulating immune cell trafficking to sites of inflammation. It may be crucial in the development of acute graft-versus-host disease (GvHD) and other inflammatory conditions. Clinical studies by others further support the concept that blocking CCR5 using a chemical inhibitor can reduce the clinical impact of acute GvHD without significantly affecting the engraftment of transplanted bone marrow stem cells. CytoDyn is currently conducting a Phase 2 clinical study with leronlimab to support further the concept that the CCR5 receptor on engrafted cells is critical for the development of acute GvHD, blocking the CCR5 receptor from recognizing specific immune signaling molecules is a viable approach to mitigating acute GvHD. The FDA has granted orphan drug designation to leronlimab for the prevention of GvHD.
About CytoDyn CytoDyn is a late-stage biotechnology company developing innovative treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. CCR5 appears to play a critical role in the ability of HIV to enter and infect healthy T-cells. The CCR5 receptor also appears to be implicated in tumor metastasis and immune-mediated illnesses, such as GvHD and NASH. CytoDyn has successfully completed a Phase 3 pivotal trial with leronlimab in combination with standard antiretroviral therapies in HIV-infected treatment-experienced patients. CytoDyn filed its BLA in April 2020 to seek FDA approval for leronlimab as a combination therapy for highly treatment experienced HIV patients, and submitted additional FDA requested clinical datasets on May 11, 2020. CytoDyn is also conducting a Phase 3 investigative trial with leronlimab as a once-weekly monotherapy for HIV-infected patients. CytoDyn plans to initiate a registration-directed study of leronlimab monotherapy indication. If successful, it could support a label extension. Clinical results to date from multiple trials have shown that leronlimab can significantly reduce viral burden in people infected with HIV. No drug-related serious site injection reactions reported in about 800 patients treated with leronlimab and no drug-related SAEs reported in patients treated with 700 mg dose of leronlimab. Moreover, a Phase 2b clinical trial demonstrated that leronlimab monotherapy can prevent viral escape in HIV-infected patients; some patients on leronlimab monotherapy have remained virally suppressed for more than five years. CytoDyn is also conducting a Phase 2 trial to evaluate leronlimab for the prevention of GvHD and a Phase 1b/2 clinical trial with leronlimab in metastatic triple-negative breast cancer. More information is at http://www.cytodyn.com.
Forward-Looking Statements This press release contains certain forward-looking statements that involve risks, uncertainties and assumptions that are difficult to predict. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as believes, hopes, intends, estimates, expects, projects, plans, anticipates and variations thereof, or the use of future tense, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. Forward-looking statements specifically include statements about leronlimab, its ability to have positive health outcomes, the possible results of clinical trials, studies or other programs or ability to continue those programs, the ability to obtain regulatory approval for commercial sales, and the market for actual commercial sales. The Companys forward-looking statements are not guarantees of performance, and actual results could vary materially from those contained in or expressed by such statements due to risks and uncertainties including: (i) the sufficiency of the Companys cash position, (ii) the Companys ability to raise additional capital to fund its operations, (iii) the Companys ability to meet its debt obligations, if any, (iv) the Companys ability to enter into partnership or licensing arrangements with third parties, (v) the Companys ability to identify patients to enroll in its clinical trials in a timely fashion, (vi) the Companys ability to achieve approval of a marketable product, (vii) the design, implementation and conduct of the Companys clinical trials, (viii) the results of the Companys clinical trials, including the possibility of unfavorable clinical trial results, (ix) the market for, and marketability of, any product that is approved, (x) the existence or development of vaccines, drugs, or other treatments that are viewed by medical professionals or patients as superior to the Companys products, (xi) regulatory initiatives, compliance with governmental regulations and the regulatory approval process, (xii) general economic and business conditions, (xiii) changes in foreign, political, and social conditions, and (xiv) various other matters, many of which are beyond the Companys control. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the Securities and Exchange Commission. Except as required by law, the Company does not undertake any responsibility to update any forward-looking statements to take into account events or circumstances that occur after the date of this press release.
CYTODYN CONTACTSInvestors: Dave Gentry, CEO RedChip Companies Office: 1.800.RED.CHIP (733.2447) Cell: 407.491.4498 dave@redchip.com
Follow this link:
CytoDyn to Offer No-Cost Exploratory Laboratory Testing for Childhood Inflammatory Disease Associated with COVID-19 - The Bakersfield Californian
- Bone Marrow Stem Cells [Last Updated On: June 24th, 2011] [Originally Added On: June 24th, 2011]
- Stem cells in bone marrow are being used to treat EB [Last Updated On: June 24th, 2011] [Originally Added On: June 24th, 2011]
- Stem cells in bone marrow are being used to treat EB [Last Updated On: June 25th, 2011] [Originally Added On: June 25th, 2011]
- Peripheral Artery Disease: Can Progenitor Cells Help? [Last Updated On: June 25th, 2011] [Originally Added On: June 25th, 2011]
- Bone Marrow Producing Insulin [Last Updated On: June 25th, 2011] [Originally Added On: June 25th, 2011]
- Stem Cells Reversing Endothelial Senescence [Last Updated On: June 25th, 2011] [Originally Added On: June 25th, 2011]
- Peripheral Artery Disease: Can Progenitor Cells Help? [Last Updated On: June 26th, 2011] [Originally Added On: June 26th, 2011]
- Science behind Enhancing Adult Stem Cells for wellbeing [Last Updated On: June 26th, 2011] [Originally Added On: June 26th, 2011]
- Bone Marrow Stem Cell Applications [Last Updated On: June 26th, 2011] [Originally Added On: June 26th, 2011]
- Immune Modulation by Bone Marrow Mesenchymal Stem Cells [Last Updated On: June 26th, 2011] [Originally Added On: June 26th, 2011]
- Expansion of Stem Cells by Valproic Acid [Last Updated On: June 27th, 2011] [Originally Added On: June 27th, 2011]
- STEM CELLS FOR MACULAR DEGENERATION Sam Smith's story.wmv [Last Updated On: June 27th, 2011] [Originally Added On: June 27th, 2011]
- StemLife's First Cord Blood Stem Cell Transplant Recipient [Last Updated On: June 28th, 2011] [Originally Added On: June 28th, 2011]
- Bone Marrow Differentiation to Heart? YES [Last Updated On: June 28th, 2011] [Originally Added On: June 28th, 2011]
- STEM CELLS FOR OTHER USES Interview with Sam Smith.wmv [Last Updated On: June 29th, 2011] [Originally Added On: June 29th, 2011]
- StemLife's First Cord Blood Stem Cell Transplant Recipient [Last Updated On: June 30th, 2011] [Originally Added On: June 30th, 2011]
- Bone marrow transplantation HD, ENG subtitles [Last Updated On: July 3rd, 2011] [Originally Added On: July 3rd, 2011]
- Cord Blood and Bone Marrow Stem Cells for Liver Failure [Last Updated On: July 4th, 2011] [Originally Added On: July 4th, 2011]
- Bone Marrow Stem Cell Applications [Last Updated On: July 4th, 2011] [Originally Added On: July 4th, 2011]
- Bone Marrow Producing Insulin [Last Updated On: July 5th, 2011] [Originally Added On: July 5th, 2011]
- Bone Marrow Stem Cell Donation [Last Updated On: July 6th, 2011] [Originally Added On: July 6th, 2011]
- Adult Stem Cells May Target and Repair Heart Attack Damage [Last Updated On: July 6th, 2011] [Originally Added On: July 6th, 2011]
- Stem cells used for medical treatment [Last Updated On: July 7th, 2011] [Originally Added On: July 7th, 2011]
- Bone marrow transplantation HD, ENG subtitles [Last Updated On: July 8th, 2011] [Originally Added On: July 8th, 2011]
- Adult Stem Cells May Target and Repair Heart Attack Damage [Last Updated On: July 8th, 2011] [Originally Added On: July 8th, 2011]
- From Surgical Repair to Stem Cell Repair: A Surgeon's Journey by Leonard Smith MD, FACS [Last Updated On: July 13th, 2011] [Originally Added On: July 13th, 2011]
- STEM CELLS - Bone Marrow Stem Cells (Balzitt).flv [Last Updated On: July 14th, 2011] [Originally Added On: July 14th, 2011]
- Spirulina DLA Naturals [Last Updated On: July 15th, 2011] [Originally Added On: July 15th, 2011]
- Spirulina DLA Naturals [Last Updated On: July 16th, 2011] [Originally Added On: July 16th, 2011]
- Insidermedicine In 60 - January 6, 2011 [Last Updated On: July 16th, 2011] [Originally Added On: July 16th, 2011]
- Christian Drapeau Talk About - Adult Stem Cells and StemEnhance./StemTech [Last Updated On: July 18th, 2011] [Originally Added On: July 18th, 2011]
- The potential of stem cells [Last Updated On: July 18th, 2011] [Originally Added On: July 18th, 2011]
- Insidermedicine In 60 - March 11, 2011 [Last Updated On: July 20th, 2011] [Originally Added On: July 20th, 2011]
- Blind Girl get's cure you need to see to believe" [Last Updated On: July 23rd, 2011] [Originally Added On: July 23rd, 2011]
- STEM CELLS - Bone Marrow Stem Cells (Balzitt).flv [Last Updated On: July 23rd, 2011] [Originally Added On: July 23rd, 2011]
- Expansion of Stem Cells by Valproic Acid [Last Updated On: July 23rd, 2011] [Originally Added On: July 23rd, 2011]
- Blind Girl get's cure you need to see to believe" [Last Updated On: July 24th, 2011] [Originally Added On: July 24th, 2011]
- LifeCell in Kalaignar Seithigal,Sun News [Last Updated On: July 26th, 2011] [Originally Added On: July 26th, 2011]
- Science behind Enhancing Adult Stem Cells for wellbeing [Last Updated On: July 27th, 2011] [Originally Added On: July 27th, 2011]
- Why treatment results vary after stem cell treatment [Last Updated On: July 27th, 2011] [Originally Added On: July 27th, 2011]
- From Surgical Repair to Stem Cell Repair: A Surgeon's Journey by Leonard Smith MD, FACS [Last Updated On: August 3rd, 2011] [Originally Added On: August 3rd, 2011]
- Insidermedicine In 60 - March 11, 2011 [Last Updated On: August 4th, 2011] [Originally Added On: August 4th, 2011]
- Why STEM-Enhance? [Last Updated On: August 10th, 2011] [Originally Added On: August 10th, 2011]
- Stem cells Transplatation in Completed Paralyze Dog. [Last Updated On: August 12th, 2011] [Originally Added On: August 12th, 2011]
- Stem cells Transplatation in Completed Paralyze Dog. [Last Updated On: August 15th, 2011] [Originally Added On: August 15th, 2011]
- Best natural skin care serum using stem cell technology [Last Updated On: August 19th, 2011] [Originally Added On: August 19th, 2011]
- "Bone Marrow Stem Cells" Donald Kohn [Last Updated On: August 29th, 2011] [Originally Added On: August 29th, 2011]
- The potential of stem cells [Last Updated On: August 31st, 2011] [Originally Added On: August 31st, 2011]
- Manatee man is paralyzed, but still plenty hopeful [Last Updated On: September 4th, 2011] [Originally Added On: September 4th, 2011]
- Stem Cells and Bone Marrow Transplants by Dipnarine Maharaj MD PhD [Last Updated On: September 5th, 2011] [Originally Added On: September 5th, 2011]
- MS Cure - Introduction to stem cell bone marrow transplant in Australia [Last Updated On: September 5th, 2011] [Originally Added On: September 5th, 2011]
- Bone Marrow/Stem Cell Transplantation: An Introduction, With Sonali Smith, MD [Last Updated On: September 5th, 2011] [Originally Added On: September 5th, 2011]
- Cancer Update: Autologus Stem Cell (Bone Marrow) Transplant [Last Updated On: September 5th, 2011] [Originally Added On: September 5th, 2011]
- Bone Marrow Stem Cell Transplant Live from Top US Hospital [Last Updated On: September 5th, 2011] [Originally Added On: September 5th, 2011]
- Adult Stem Cell Mobilization from Bone Marrow (Animation) [Last Updated On: September 6th, 2011] [Originally Added On: September 6th, 2011]
- Bone Marrow / Stem Cell Transplant Recovery Fund [Last Updated On: September 7th, 2011] [Originally Added On: September 7th, 2011]
- Bone Marrow Stem Cell Expansion by HOXB4 and p21 Knock Out [Last Updated On: September 10th, 2011] [Originally Added On: September 10th, 2011]
- Adult Stem Cell Mobilization from Bone Marrow (Animation) [Last Updated On: September 10th, 2011] [Originally Added On: September 10th, 2011]
- Bone Marrow/Stem Cell Transplant [Last Updated On: September 10th, 2011] [Originally Added On: September 10th, 2011]
- Bone Marrow/Stem Cell Transplant [Last Updated On: September 11th, 2011] [Originally Added On: September 11th, 2011]
- Macular Degeneration Improved With Stem Cells [Last Updated On: September 12th, 2011] [Originally Added On: September 12th, 2011]
- Stem Cell Transplant India,Bone Marrow Transplant India,Sickle Cell Anemia Treatment India [Last Updated On: September 20th, 2011] [Originally Added On: September 20th, 2011]
- Nurses Discuss Special Bonds With Bone Marrow and Stem Cell Transplant Patients [Last Updated On: September 20th, 2011] [Originally Added On: September 20th, 2011]
- Becoming a Blood Stem Cell Donor [Last Updated On: September 20th, 2011] [Originally Added On: September 20th, 2011]
- Bone Marrow and Stem Cell Transplant Patients Share Their Stories [Last Updated On: September 20th, 2011] [Originally Added On: September 20th, 2011]
- LittleBigPlanet 2 - (WIP) Stem Cell Sackboy Bone Marrow Bugaloo [Last Updated On: September 20th, 2011] [Originally Added On: September 20th, 2011]
- LittleBigPlanet 2 - Stem Cell Sackboy Quarter 4 Update (Bone Marrow Bugaloo) [Last Updated On: September 22nd, 2011] [Originally Added On: September 22nd, 2011]
- Bone Marrow Transplant Program Continues to Grow, Make a Difference [Last Updated On: September 23rd, 2011] [Originally Added On: September 23rd, 2011]
- Can Stem Cell Prolotherapy or Bone Marrow Prolotherapy help articular cartilage defects? [Last Updated On: September 23rd, 2011] [Originally Added On: September 23rd, 2011]
- Multiple Sclerosis, Stem Cells, and Hope, Part 2 [Last Updated On: September 23rd, 2011] [Originally Added On: September 23rd, 2011]
- Bone Marrow Transplant Program Continues to Grow, Make a Difference [Last Updated On: September 23rd, 2011] [Originally Added On: September 23rd, 2011]
- How to be an Anthony Nolan blood stem cell donor [Last Updated On: September 23rd, 2011] [Originally Added On: September 23rd, 2011]
- Stem Cells extracted from bone marrow [Last Updated On: September 23rd, 2011] [Originally Added On: September 23rd, 2011]
- Calum's stem cell donation for Anthony Nolan [Last Updated On: September 23rd, 2011] [Originally Added On: September 23rd, 2011]
- Cancer Update: Autologus Stem Cell (Bone Marrow) Transplant [Last Updated On: September 23rd, 2011] [Originally Added On: September 23rd, 2011]
- Bone Marrow - Stem Cell Prolotherapy [Last Updated On: September 24th, 2011] [Originally Added On: September 24th, 2011]
- Bone Marrow Stem Cell Aspiration and Re-Injection with PRP for Osteoarthritis by Dr Adelson [Last Updated On: September 24th, 2011] [Originally Added On: September 24th, 2011]
- Mesenchymal stem cells and marrow stromal cells---2nd--- [Last Updated On: September 25th, 2011] [Originally Added On: September 25th, 2011]
- Stem Cell Injections - Bone Marrow Prolotherapy - treatment for arthritis [Last Updated On: September 25th, 2011] [Originally Added On: September 25th, 2011]
- Chat w/ Dr. Maharaj, founder of S. FL. Bone Marrow/Stem Cell Transplant Institute [Last Updated On: September 25th, 2011] [Originally Added On: September 25th, 2011]